Serum neurofilament-light and glial fibrillary acidic protein levels in hydroxychloroquine-treated primary progressive multiple sclerosis

被引:7
|
作者
Camara-Lemarroy, Carlos [1 ,2 ,3 ]
Silva, Claudia [1 ,2 ]
Gohill, Jit [4 ]
Yong, V. Wee [1 ,2 ]
Koch, Marcus [1 ,2 ,5 ]
机构
[1] Univ Calgary, Dept Clin Neurosci, Room 178,Heritage Med Res Bldg,3330 Hosp Dr NW, Calgary, AB T2N 4N1, Canada
[2] Univ Calgary, Hotchkiss Brain Inst, Calgary, AB, Canada
[3] UANL Sch Med, Monterrey, Mexico
[4] Univ Calgary, Dept Surg, Sect Ophthalmol, Calgary, AB, Canada
[5] Univ Calgary, Dept Community Hlth Sci, Calgary, AB, Canada
关键词
GFAP; HCQ; multiple sclerosis; NfL; PPMS; OPTICAL COHERENCE TOMOGRAPHY; OCRELIZUMAB; PLACEBO;
D O I
10.1111/ene.15588
中图分类号
R74 [神经病学与精神病学];
学科分类号
摘要
Background In a recent trial, hydroxychloroquine (HCQ) treatment reduced the expected rate of disability worsening at 18 months in primary progressive multiple sclerosis (PPMS). Neurofilament light chain (NfL) and glial fibrillary acidic protein (GFAP) are emerging biomarkers in multiple sclerosis. Methods We measured NfL and GFAP levels in serum samples from 39 patients with inactive PPMS included in a phase II clinical trial of HCQ treatment in PPMS at multiple time points over 18 months, and investigated the association of these biomarkers with clinical disability at screening and during follow-up. Screening and 12-month retinal nerve fiber layer (RNFL) thickness was also recorded and analyzed. Results NfL and GFAP levels increased over time, but only significantly from screening to month 6. NfL and GFAP levels did not significantly increase from month 6 up to month 18. At screening, NfL and GFAP levels did not correlate with the Expanded Disability Status Scale (EDSS), and GFAP but not NfL modestly correlated with Timed 25-Foot Walk test (T25FW). Screening NfL and GFAP levels did not predict disability worsening (>= 20% worsening on the T25FW) at month 18. RNFL thickness decreased significantly from screening to month 12 and independently predicted disability worsening. Conclusions In this cohort of people with inactive PPMS, HCQ treatment attenuated the increase of NfL and GFAP after 6 months of treatment and up to 18 months of follow-up, suggesting a treatment effect of HCQ over these biomarkers. RNFL thickness, a marker of neuroaxonal atrophy, was associated with disability worsening, and should be explored further as a prognostic marker in this population.
引用
收藏
页码:187 / 194
页数:8
相关论文
共 50 条
  • [41] Neurofilament Light Chain Correlates with Disease Activity while Both Neurofilament Light Chain and Glial Fibrillary Acidic Protein Associate with Disability in Pediatric Multiple Sclerosis
    Saucier, L.
    Healy, B. C.
    Saxena, S.
    Sanon, E. D.
    Saraceno, T. J.
    Chitnis, T.
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 232 - 233
  • [42] Can serum glial fibrillary acidic protein (GFAP) solve the longstanding problem of diagnosis and monitoring progressive multiple sclerosis
    Groen, Kira
    Lechner-Scott, Jeannette
    Pohl, Daniela
    Levy, Michael
    Giovannoni, Gavin
    Hawkes, Chris
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 50
  • [43] Evaluation of serum neurofilament light chain and glial fibrillary acidic protein in the diagnosis of Alzheimer's disease
    Fang, Tangni
    Dai, Yaqian
    Hu, Xueyi
    Xu, Yuanhong
    Qiao, Jinping
    FRONTIERS IN NEUROLOGY, 2024, 15
  • [44] Clinical implication of serum neurofilament light chain and glial fibrillary acidic protein in idiopathic transverse myelitis
    Kim, K. -W.
    Lee, E. -J.
    Jung, H. -J.
    Kim, S.
    Kim, H.
    Seo, D.
    Kim, H.
    Kim, K. -K.
    Lim, Y. -M.
    MULTIPLE SCLEROSIS JOURNAL, 2022, 28 (3_SUPPL) : 309 - 310
  • [45] Stool glial fibrillary acidic protein is a biomarker of progressive multiple sclerosis and predicts disease worsening
    Schwerdtfeger, Luke
    Montini, Federico
    Ekwudo, Millicent
    LeServe, Danielle
    Glanz, Bonnie
    Chitnis, Tanuja
    Cox, Laura
    Weiner, Howard
    MULTIPLE SCLEROSIS JOURNAL, 2023, 29 : 577 - 577
  • [46] Serum neurofilament and glial fibrillary acidic protein in idiopathic and seropositive transverse myelitis
    Lee, Hye Lim
    Seok, Jin Myoung
    Chung, Yeon Hak
    Min, Ju-Hong
    Baek, Seol-Hee
    Kim, Sung Min
    Sohn, Eunhee
    Kim, Juhyeon
    Kang, Sa-Yoon
    Hong, Yoon-Ho
    Shin, Ha Young
    Cho, Joong-Yang
    Oh, Jeeyoung
    Lee, Sang-Soo
    Kim, Sunyoung
    Kim, Su-Hyun
    Kim, Ho Jin
    Kim, Byung-Jo
    Kim, Byoung Joon
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2023, 79
  • [47] Serum total tau, neurofilament light, and glial fibrillary acidic protein are associated with mortality in a population study
    Halloway, Shannon
    Evans, Denis A.
    Desai, Pankaja
    Dhana, Klodian
    Beck, Todd
    Rajan, Kumar B.
    JOURNAL OF THE AMERICAN GERIATRICS SOCIETY, 2024, 72 (01) : 149 - 159
  • [48] Serum Neurofilament Light, Glial Fibrillary Acidic Protein and Tau Are Possible Serum Biomarkers for Activity of Brain Metastases and Gliomas
    Hepner, Adriana
    Porter, Jason
    Hare, Felicia
    Nasir, Syed Sameer
    Zetterberg, Henrik
    Blennow, Kaj
    Martin, Michael Gary
    WORLD JOURNAL OF ONCOLOGY, 2019, 10 (4-5) : 169 - 175
  • [49] The effect of aerobic exercise on Neurofilament light chain and glial Fibrillary acidic protein level in patients with relapsing remitting type multiple sclerosis
    Ercan, Zubeyde
    Bilek, Furkan
    Demir, Caner Feyzi
    MULTIPLE SCLEROSIS AND RELATED DISORDERS, 2021, 55
  • [50] Increasing Neurofilament and Glial Fibrillary Acidic Protein After Treatment Discontinuation Predicts Multiple Sclerosis Disease Activity
    Bose, Gauruv
    Healy, Brian C.
    Saxena, Shrishti
    Saleh, Fermisk
    Glanz, Bonnie I.
    Bakshi, Rohit
    Weiner, Howard L.
    Chitnis, Tanuja
    NEUROLOGY-NEUROIMMUNOLOGY & NEUROINFLAMMATION, 2023, 10 (06):